Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches

• Published in: Frontiers in cellular neuroscience Vol. 8; p. 112
• Main Authors: Morales, Inelia, Guzmán-Martínez, Leonardo, Cerda-Troncoso, Cristóbal, Farías, Gonzalo A, Maccioni, Ricardo B
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 22.04.2014; Frontiers Media S.A
• Subjects: Alzheimer's disease; Anti-inflammatory agents; Astrocytes; Brain injury; Cell cycle; Chemokines; Curcumin; Cytokines; Dementia; Dementia disorders; Disease; Inflammation; Innate immunity; Microglial cells; Neurodegeneration; Neurodegenerative diseases; Neuroimmunomodulation; Neuroscience; Proteins; Tau protein; Trauma; β-Amyloid; Chile; astrocytes; Alzheimer disease; neuroinflammation; microglia; nutraceuticals
• ISSN: 1662-5102; 1662-5102
• DOI: 10.3389/fncel.2014.00112

Alzheimer disease (AD) is the most common cause of dementia in people over 60 years old. The molecular and cellular alterations that trigger this disease are still diffuse, one of the reasons for the delay in finding an effective treatment. In the search for new targets to search for novel therapeutic avenues, clinical studies in patients who used anti-inflammatory drugs indicating a lower incidence of AD have been of value to support the neuroinflammatory hypothesis of the neurodegenerative processes and the role of innate immunity in this disease. Neuroinflammation appears to occur as a consequence of a series of damage signals, including trauma, infection, oxidative agents, redox iron, oligomers of τ and β-amyloid, etc. In this context, our theory of Neuroimmunomodulation focus on the link between neuronal damage and brain inflammatory process, mediated by the progressive activation of astrocytes and microglial cells with the consequent overproduction of proinflammatory agents. Here, we discuss about the role of microglial and astrocytic cells, the principal agents in neuroinflammation process, in the development of neurodegenerative diseases such as AD. In this context, we also evaluated the potential relevance of natural anti-inflammatory components, which include curcumin and the novel Andean Compound, as agents for AD prevention and as a coadjuvant for AD treatments.